Navigation Links
Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
Date:11/23/2011

OSAKA, Japan and DEERFIELD, Ill., Nov. 23, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet. The FDA is expected to review the NDA submission within the next ten months, the standard review period for a new application.

"This NDA submission further extends Takeda's commitment to offering patients with type 2 diabetes a range of therapeutic options to help them manage their condition," noted Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "The worldwide incidence of type 2 diabetes continues to expand at a rapid rate and we continue our research into additional medications to treat these patients."

Alogliptin is a selective dipeptidyl peptidase IV inhibitor (DPP-4i) under investigation in the U.S. for the treatment of type 2 diabetes as an adjunct to diet and exercise. Discovered by Takeda San Diego, Inc., alogliptin is designed to slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), which play roles in regulating blood glucose levels. Metformin is a widely used diabetes medication that acts primarily by reducing the amount of glucose produced by the liver. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels.  

Common adverse reactions reported in greater than or equal to 5 percent of patients treated with co-administration of alogliptin with metformin were: upper respiratory tract infection, nasopharyngitis, creatinine renal clearance decreased, diarrhea, headache, hypertension, and urina
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. U.S. Food and Drug Administration (FDA) Delays Review of Takedas Investigational Type 2 Diabetes Therapies, Alogliptin and Alogliptin/Pioglitazone
2. Takeda Announces PDUFA Action Date for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
3. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
4. Takeda Completes Acquisition and Names New CEO of Nycomed
5. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
6. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
7. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
8. Takeda to Acquire Nycomed
9. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
10. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
11. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across ... virus, select Meijer pharmacies in Michigan ... to eligible patients, enabling Meijer pharmacists to administer tests and, ... set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health ... several new IT value-added reseller (VAR) national contracts that ... goods and services at lower costs. These include manufacturer ... such as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... 2012  Pharmaceutical marketers who need to calibrate multi-channel marketing ... limitless questions. SyntheSight™ , a new ... with a patent-pending IntelliScore™ , provides ... leaders find answers. SyntheSight ...
... the fastest growing Electronic Medical Record ... its award winning e-prescribing software has been revamped; ... experience based on community feedback. The company,s free ... interactions for medical professionals in 2011 alone. ...
Cached Medicine Technology:RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 2RMi Introduces SyntheSight™ Pharma Multi-Channel Optimization Suite 3Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 2Practice Fusion's Top-Rated e-Prescribing Software Gets a Doctor-Driven Makeover 3
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... all types of cancer sends the protein factories in ... tumour,s uncontrolled growth, new research suggests. , Scientists at ... trigger responsible for ratcheting up activity of the endoplasmic ... building blocks cancer cells need to keep growing. , ... controls the flow of messages to the endoplasmic reticulum ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... the same protein that was a primary mediator of the birth ... multiple myeloma , says the study,s senior investigator, Keith ... Dr. Stewart presented the results at the 53rd annual meeting of ... The drug thalidomide achieved infamy in the early 1960s as the ...
... December 10, 2011) Symptoms improved significantly in adults ... treatment with gene therapy developed by researchers at St. ... be safe in a clinical trial conducted at the ... findings of the six-person study mark the first proof ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Flu vaccination is ... protect your health during the flu season, but too few ... shrug off concerns about the flu, yet every year it ... 200,000 to the hospital and killing thousands," Dr. Thomas Slama, ...
... so many postmenopausal women who are treated for estrogen-sensitive ... disease from recurring? The first study to actually ... largest, most scientifically rigorous study to examine the question ... of the medications, side effects, which are more severe ...
... present in dangerous quantities in the Vauchre river basin ... be presented the 9th of December, at the American ... to kill microorganisms, called biocides, are added to exterior ... Washed off of building facades during heavy rains, however, ...
... 9 (HealthDay News) -- ,Preschool children who were born just ... behavioral and emotional problems, new research suggests. Researchers in ... development tests on about 1,500 children when they were 4 ... and nearly 1,000 were born between 32 and 35 weeks ...
Cached Medicine News:Health News:Mayo Clinic: How patients will respond to immunomodulator therapy for multiple myeloma 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 2Health News:Gene therapy achieves early success against hereditary bleeding disorder 3Health News:Americans Encouraged to Get Flu Vaccine 2Health News:Why women quit breast cancer drugs early 2Health News:Why women quit breast cancer drugs early 3Health News:Model shows how façade pollutants make it into the environment 2Health News:Behavior Problems May Surface in Preemies by Preschool 2
... ExTOL systems feature your choice of ... electrocardiographs, an easy-to-operate monitor and the ... exercise stress testing systems also feature ... point, pre-programmed or custom protocols, and ...
... w/ Remote/Controller. Includes Full Range ... Children. Multiple 20/20 slides. Polarized ... allows you to customize your slide choices. ... with Long Life. Variety of mounting options. ...
... Ultimate in Stability. ... stabilizer features superior arm ... in the clamp/turret mechanism. ... features the ultimate flexibility ...
... leader in beating heart bypass, comes the ... NS device is the first leap in ... of surgical revascularization.,The Starfish NS Heart Positioner ... Small Thoracotomy (MVST) procedure without CPB and ...
Medicine Products: